株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

末梢動脈疾患(PAD)/末梢血管疾患(PVD):世界の臨床試験レビュー

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Global Clinical Trials Review, H2, 2016

発行 GlobalData 商品コード 289942
出版日 ページ情報 英文 273 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
末梢動脈疾患(PAD)/末梢血管疾患(PVD):世界の臨床試験レビュー Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Global Clinical Trials Review, H2, 2016
出版日: 2016年09月30日 ページ情報: 英文 273 Pages
概要

当レポートでは、世界の末梢動脈疾患(PAD)/末梢血管疾患(PVD)治療薬の臨床試験(治験)について調査分析し、地域・進捗状況・フェーズ(相)・募集状況別の実施件数や、代表的なスポンサー、開発中の治療薬の情報、臨床試験プロファイルなどを提供して、概略以下の構成でお届けいたします。

目次

イントロダクション

地域別の臨床試験

  • 国別の臨床試験
    • アジア太平洋地域の主要5ヶ国
    • 欧州の主要5ヶ国
    • 北米の主要国
    • 中東・アフリカの主要5ヶ国
    • 中南米の主要国

BRIC諸国の臨床試験

G7諸国の臨床試験

G7諸国の臨床試験:段階別

E7諸国の臨床試験

E7諸国の臨床試験:段階別

フェーズ別の臨床試験

進捗状況

段階別の臨床試験

未完了の臨床試験

一定期間に採用された被験者

有力スポンサー

  • 参加している主要企業

有望な治療薬の比較

臨床試験プロファイル

  • 主要企業の臨床試験の概要
    • Sanofi
    • AstraZeneca PLC
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Utrecht Holdings
    • Foxhollow Technologies, Inc.(休止中)
    • AnGes MG, Inc.
    • Bracco Diagnostics Inc.
    • Bayer AG
    • ActivBiotics Canada, Inc.
  • 主要大学・研究機関・病院の臨床試験の概要
    • National Heart, Lung, and Blood Institute
    • Medical University of Vienna
    • Northwestern University
    • University Hospital, Angers
    • 名古屋大学
    • Duke University
    • University of Virginia
    • The University of Aberdeen
    • Brigham and Women's Hospital
    • Academic Medical Centre

主要な臨床プロファイル(5件)

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC3802CTIDB

GlobalData's clinical trial report, "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Global Clinical Trials Review, H2, 2016" provides an overview of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) clinical trials scenario. This report provides top line data relating to the clinical trials on Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) to Cardiovascular Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) to Cardiovascular Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)
      • Oct 04, 2016: AstraZeneca reports top-line results from the Brilinta EUCLID trial in patients with peripheral artery disease
      • Sep 29, 2016: Low levels of endogenous anti-PC identified as a novel risk factor for vein bypass graft failure and cardiovascular complications in PAD patients
      • Sep 28, 2016: Athera presents positive First-in-Patient data with their new antibody against immunovascular disease at ESVS
      • Aug 11, 2016: Athera Biotechnologies completes First-in-Patient Study with New Antibody Against Immunovascular Disease
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, Global, Clinical Trials by Region, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*
  • Proportion of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) to Cardiovascular Clinical Trials, G7 Countries (%), 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) to Cardiovascular Clinical Trials, E7 Countries (%), 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*
  • Proportion of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) to Cardiovascular Clinical Trials, G7 Countries (%), 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) to Cardiovascular Clinical Trials, E7 Countries (%), 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top